Table 1.

5-year Progression-Free Survival and Disease-Specific Survival by Anatomic and Prognosis Stage of TNBCs included in SYSUCC-PWH cohort (N = 611)

	Stage	No. at risk	5-year PFS (95% CI)	p-value	No. at risk	5-year DSS (95% CI)	p-value
AS	I(A*)	100	86.5(76.2,92.5)	< 0.001**	100	92.9(83.4,97.0)	0.001**
	II	371	82.0(77.0,86.0)	0.001#	371	90.6(86.3,93.6)	0.080#
	IIA	240	87.9(82.4,91.9)		240	92.7(87.7,95.7)
	IIB	131	71.0(60.9,79.0)		131	86.2(76.8,92.0)
	III	140	50.9(41.1,59.8)	0.045△	140	74.1(64.2,81.7)	0.099△
	IIIA	78	56.6(43.7,67.6)		78	80.4(67.8,88.5)
	IIIB	29	55.2(28.6,75.4)		29	51.4(23.1,73.9)
	IIIC	33	34.9(18.3,52.2)		33	70.4(46.9,85.0)
PS	I	100	86.5(76.2,92.5)	< 0.001**	100	92.9(83.4,97.0)	< 0.001**
	IA	3	NA	NA	3	NA	NA
	IB	97	86.0(75.4,92.3)		97	92.7(88.5,97.0)
	II	291	83.9(78.3,88.2)	0.002#	291	91.9(87.2,94.9)	0.209#
	IIA	240	87.9(82.4,91.9)		240	92.7(89.7,95.7)
	IIB	51	64.1(46.1,77.5)		51	87.3(79.4,95.1)
	III	220	60.1(52.3,66.9)	< 0.001△	220	78.2(70.7,83.9)	0.023△
	IIIA	83	74.7(62.2,83.6)		83	85.5(78.7,92.3)
	IIIB	26	73.7(50.4,87.3)		26	83.5(72.5,94.5)
	IIIC	111	44.9(34.0,55.1)		111	70.7(61.8,79.7)

**Log-rank test comparing proportions among all stage; ^#Log-rank test comparing proportions among Stage II; ^△Log-rank test comparing proportions among Stage III; *No case was classified as anatomic stage IB in this cohort

TNBC triple negative breast cancer, AS anatomic stage, PS prognosis stage, PFS progression-free survival, DSS disease specific survival, CI confidence interval